ELISA is the gold standard of *in vitro* diagnostics (IVD) during the last five decades for analysis of biomarkers and important analytes in healthcare and diversified analytical settings. With over 300,000 peer-reviewed articles to date, ELISA-based technologies have open up a lucrative, commercial market. Despite ongoing developments in immunosensors, labs-on-chips, and microfluidic and point-of-care technologies, ELISA with high throughput and omnipotent nature has been unmatched in reliability for the monitoring and management of disease markers. It is still the most widely used immunoassay format by pharmaceutical industries for routine monitoring of drugs and drug impurities (e.g. Chinese hamster ovary protein and monocyte chemotactic protein). Competing immunoassay technology must be compared to ELISA for precision and other analytical parameters.

Defined plasma biomarkers are of unique diagnostic relevance for early preventive intervention in chronic inflammatory diseases, highly prevalent in the Western world. One of those biomarkers is HFA where a highly sensitive and rapid assay is of value when combined with sensitive measurements of C-reactive protein[@b1]. HFA is a product of the liver and its concentration decreases during the acute phase reaction. Due to its anti-inflammatory properties by counteracting proinflammatory cytokine production, quantification in body fluids is highly relevant in guiding diagnostics and therapy of infection-independent diseases of liver, heart and vasculature. *In vivo*, HFA functions as an inhibitor of soft tissue calcification and is a specific biomarker for hepatocellular carcinoma[@b2] and atherosclerosis[@b3], and associated with arthritis[@b4], cardiovascular diseases[@b5][@b6][@b7], malaria[@b8], diabetes[@b9], and metabolic syndrome[@b10], as well as neurological diseases such as multiple sclerosis[@b11].

The last two decades have witnessed considerable advances in the development of improved immunoassay procedures for IVD including improved antibody (Ab) immobilization chemistries, signal enhancement strategies using micro-/nanomaterials or polymers, novel lab-on-a-chip technologies, biosensors and novel immunoassay formats. In all cases, the development of an appropriate Ab immobilization strategy is a critical requirement that significantly affects the analytical performance of an immunoassay[@b12][@b13][@b14]. Examples range from adsorption, oriented binding using fragment crystallizable (F~c~) proteins, covalent binding using cross-linkers, site-directed immobilization, and non-covalent binding[@b15][@b16][@b17][@b18][@b19][@b20][@b21]. However, most of these procedures employ a complex multi-step procedure involving costly crosslinking agents.

This article describes a simple immobilization-based sandwich ELISA procedure for the development of rapid, low-cost and highly-sensitive IVD kits. The new immobilization format (NIF) only involves the dilution of the antibody in APTES to form a stable complex. APTES-polymer/Ab complexes sorbed on the microtiter plate (MTP) will be evaluated with respect to detection limit, analytical sensitivity, storage stability and its applicability for detecting HFA in human whole blood and plasma.

Results
=======

In this procedure, the capture Ab was admixed with 1% (v/v) APTES (1:1 v/v mixture), dispensed into the MTP wells and incubated for 30 min ([Figure 1](#f1){ref-type="fig"}). Under the optimized condition ([Supplementary Figures S1a--b](#s1){ref-type="supplementary-material"}), HFA from 4.9 to 20,000 pg mL^−1^ was detected with linearity of 156 to 20,000 pg mL^−1^ ([Figure 2a](#f2){ref-type="fig"}). The estimated limit of detection (LOD) and analytical sensitivity were 7 pg mL^−1^ and 10 pg mL^−1^, respectively. The intraday variability of five assay repeats (in triplicate) in a single day ranged from 1.2 to 8.5, while the interday variability of five assay repeats (in triplicate) on five consecutive days was between 2.1 to 10.2. With a maximal half-effective concentration (EC~50~) of 2.6 ng mL^−1^, the NIF was highly specific to HFA without any interference from immunological reagents in different process controls ([Figure 2b](#f2){ref-type="fig"}).

The NIF was compared with a commercial ELISA kit and a typical sandwich ELISA procedure with covalently cross-linked Ab on APTES-functionalized surfaces[@b17][@b22]. All immunoassays were performed under the same conditions with the same assay components to minimize experimental variability. The NIF outperformed conventional immobilization format (CIF)-based sandwich ELISA with 28-fold faster Ab immobilization and 51-fold more sensitivity. Compared to the covalent immobilization format (CovIF) that involves the covalent crosslinking of Ab to the APTES-functionalized MTP, it is still 5-fold faster in terms of Ab immobilization and 3-fold more sensitive ([Table 1](#t1){ref-type="table"}, [Supplementary Table S1](#s1){ref-type="supplementary-material"}). The Ab immobilization density of the NIF estimated by bicinchoninic acid protein assay was compared favorably with the results obtained by the CIF, CovIF and a new covalent immobilization format (NCIF) (which involves covalent antibody immobilization involving 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)-activated anti-HFA Ab diluted in APTES (for covalent binding of Ab to APTES into KOH-pretreated MTP wells) ([Supplementary Figure S2](#s1){ref-type="supplementary-material"}). Hence, the NIF is the most sensitive with minimal reagents and analysis time for the detection of HFA compared to various ELISA formats.

Central to the NIF is the sorption of the APTES-polymer/Ab complex to the MTP surface. To elucidate the binding of the complex to a polystyrene (PS) MTP in the absence of a crosslinker, immunoglobulin G (IgG) bovine was used as the model. PS beads were immersed in a solution of APTES/IgG in PBS buffer (0.2 mg/mL IgG and 0.5% APTES) for 30 min. The IgG/APTES solution was decanted and the resulting PS beads were washed five times with PBS buffer, followed by three times with deionized water to remove residual Na~2~HPO~4~ and KH~2~PO~4~ salts that will interfere with Fourier transform infrared spectroscopy (FTIR) and energy-dispersive X-ray (EDX) analyses. The IgG concentration was increased to provide greater peak intensity for IgG bands in the FTIR spectra for facilitating bonding elucidation. In aqueous solution, APTES reacts with the free hydroxyls of an oxidized substrate by S~N~2 exchange with loss of ethanol. The next step is condensation that leads to polymerization when an APTES molecule forms a siloxane with its neighboring APTES ([Figure 1](#f1){ref-type="fig"}).

[Figure 3](#f3){ref-type="fig"} shows five FTIR spectra: PS, PS+APTES, PS+APTES+IgG, PS+IgG and IgG. PS exhibits the usual FTIR peaks consistent for all PS derivatives. Upon addition of APTES, the spectrum shows the Si-O-Si character at 1154 cm^−1^, with 1671 cm^−1^ and a broad 3400 cm^−1^ peaks for the primary NH, confirming the presence of APTES and its polymerization[@b17][@b23]. For derivatives with IgG, additional bands for the amides at 1656, 1548 cm^−1^ with broad OH, NH bands centered at 3305 cm^−1^ that match with the IgG spectrum, although the two peaks for IgG at 1387 and 1231 cm^−1^ have diminished in those PS derivatives. The bands associated with the PO~4~ buffer salts are not present in the spectra to obscure the identity of the bands of interest. EDX analysis of the materials shows that the Si wt.% content is 0.07% for the PS derivatives with APTES with the absence of Na, K and P from the PBS buffer salts, confirming the validity of the water-wash procedure prior to FTIR acquisition. The amount of APTES bound to PS is low, but consistent with the fact that PS lacks the polar, hydrogen bond accepting groups that promote the initial adsorption chain reaction postulated for the binding of APTES to different polymers with available surface hydroxyl groups[@b24].

IgG may physically adsorb to the PS surface by interaction with the hydrophobic groups of antibody molecules without the need for APTES[@b25]. When PS was immersed in a PBS solution of IgG, IgG bands were present in the purified PS+IgG FTIR spectrum ([Figure 3](#f3){ref-type="fig"}, purple band). Since no coupling agents were employed to initiate the amide coupling between APTES and IgG, the binding of IgG to PS must be one of physical adsorption. The presence of water has two effects in the binding scheme of PS with APTES and IgG. Water can render the amine groups of APTES to be positively charged, allowing the APTES to bind to the anionic carboxylate groups of IgG through electrostatic interaction[@b26]. Water can also catalyze the polymerization of APTES as it hydrolyzes the ethoxy groups to give reactive silanol groups[@b23], which would lead to the formation of Si-O-Si bonds detected in the PS+APTES+IgG FTIR spectrum.

PS was hydroxylated by KOH and followed by EDC coupling of IgGs as a covalent immobilization control in NCIF. The reactivity of PS with KOH is negligible as evident by very little change in the FTIR spectrum ([Supplementary Figure S3](#s1){ref-type="supplementary-material"}). The amide bond formation between EDC-activated IgG and APTES displays two new bands at 1552 cm^−1^ and 1642 cm^−1^ ([Supplementary Figure S3](#s1){ref-type="supplementary-material"}, inset), which are mutually exclusive from the amide bands associated with the bound IgG. The peak at 1154 cm^−1^ reflects the polymerization of APTES (Si-O-Si bond) as described previously. Using anti-HFA Ab, the NCIF control offered no better analytical performance compared to the NIF ([Supplementary Figure S4](#s1){ref-type="supplementary-material"}). It was reasoned that a lower Ab immobilization density was due to a decrease in hydrophobic character for the covalently coupled APTES-Ab entity.

The NIF is multisubstrate-compatible and adaptable to various commercial substrates including the modified MTP format ([Supplementary Figure S5](#s1){ref-type="supplementary-material"})[@b27]. The detection of HFA spiked in diluted human whole blood and plasma ([Figure 2c](#f2){ref-type="fig"}) using the NIF exhibited similar precision as the commercial kit, showing its applicability for the determination of HFA in clinical and bioanalytical settings ([Table 2](#t2){ref-type="table"}). The NIF-based sandwich ELISA is the most sensitive immunoassay format in comparison to the commercial and previously developed sandwich ELISA formats for HFA ([Table 3](#t3){ref-type="table"}). The stability of Ab immobilized on MTPs was assessed over a two months period at 4°C in 0.1 M PBS (pH 7.4). No significant decrease in the Ab functional activity or FTIR signature was observed after eight weeks ([Figure 2d](#f2){ref-type="fig"}, [Supplementary Figure S6](#s1){ref-type="supplementary-material"}), attesting the leach-proof Ab immobilization. Lastly, the NIF was applicable for detecting C-reactive protein (CRP), human albumin and human lipocalin-2 ([Figure 4](#f4){ref-type="fig"}) with superior performance over the commercial kit.

Discussion
==========

The NIF was developed through physical adsorption of APTES-polymer/Ab complexes onto a MTP in just 30 min. The improved analytical performance, high simplicity and cost-effectiveness of the NIF was compared to commercial sandwich ELISA kits with high protein immobilization density, prolonged stability, high reproducibility and less biofouling and interferences[@b28][@b29][@b30][@b31][@b32][@b33][@b34]. The NIF, where APTES serves as a diluting and binding agent for anti-HFA capture Ab rather than a surface functionalization agent, demonstrates superior analytical performance and high stability.

With the NIF, only 0.5% APTES was used in the new procedure as compared to 2% APTES for the step-wise binding of Ab onto an APTES-functionalized PS surface[@b17] in CovIF. The presence of the aqueous PBS buffer has two effects in the binding scheme of PS with APTES and Ab. Water can catalyze the polymerization of APTES as it hydrolyzes the ethoxy groups to reactive silanol groups (see [Figure 1](#f1){ref-type="fig"})[@b23]. Confirmation of polymerization of APTES (Si-O-Si bond) is given by the band at 1154 cm^−1^ in the FTIR spectra of APTES-possessing species. There is the potential for polymerization of the APTES to form single and multilayers of APTES. In horizontal polymerization with respect to the --(CH~2~)~2~NH~2~ plane, the binding is strong owing to ionic interactions of the two carboxylate groups of the Ab (heavy chain and/or light chain) with two adjacent amino groups of the APTES polymer network. Water can also render the amine groups of APTES to be positively charged, thereby allowing the APTES to bind to the anionic carboxylate groups of Ab via electrostatic interaction ([Figure 1](#f1){ref-type="fig"})[@b26]. In addition, the silanol group is also capable of displaying intra and inter ionic interactions with the amino groups of APTES and Ab (heavy chain and/or light chain). The silanol and amino groups of APTES also display extensive hydrogen bonding with the amino and carboxylic group of the Ab to form a stable APTES-Ab polymer network. One might anticipate a more favorable interaction between Ab and APTES in the liquid form compared to that of Ab with the APTES-functionalized surface. The orientation of bound Ab might also affect its bioanalytical performance.

Typically without KOH/plasma treatment, the number of APTES molecules bound to PS is low due to the lack of the polar, hydrogen bond accepting groups that promote an initial adsorption chain reaction postulated for the binding of APTES to different polymers[@b24]. However, Ab may physically adsorb to the surface of PS by interaction with the hydrophobic groups of Ab molecules without the need for APTES[@b25]. Since the new procedure does not use crosslinking agents to initiate any amide coupling between APTES and Ab, physical adsorption could be attributed to the binding of Ab to the surface. Considering slight hydrophobicity of the aliphatic chain of APTES[@b35], a higher Ab immobilization density could be achieved to promote greater physical adsorption of the pre-formed APTES polymer-Ab complex onto the PS surface. Based on the extreme simplicity and time saving granted by the NIF, the end-users can prepare the anti-HFA capture Ab-bound plates just before their intended use. This obviates the need for storing Ab-prebound MTPs, which can lead to tremendous cost-savings and improved analytical performance due to the skipping of storage effects. The NIF is generic and applicable for detecting three selected biomarkers; therefore, this assay format will be of immense utility in the field of sandwich ELISA-based IVD kits.

Methods
=======

Ab immobilization and HFA ELISA
-------------------------------

The anti-HFA (8 μg/mL in PBS) was mixed with 1% APTES in the ratio of 1:1 (v/v). Thereafter, the anti-HFA solution, with a final concentration of 4 μg/mL in 0.5% APTES, was added to the MTP wells and incubated for 30 min at room temperature. After washing with PBS, the anti-HFA-bound MTP wells were blocked with 1% (v/v) bovine serum albumin (BSA, diluted in 0.1 M PBS, pH 7.4) for 30 min and washed with PBS. The anti-HFA-bound MTP wells were then incubated with various HFA concentrations (4.9 pg mL^−1^ to 20 ng mL^−1^) for 1 h and washed with PBS. Thereafter, biotinylated anti-HFA (200 ng mL^−1^) was provided and incubated for 1 h followed by PBS washings. Subsequently, HRP-conjugated streptavidin, at a dilution of 1:200, was added to the MTP wells and incubated for 20 min followed by PBS washings. Such steps were performed at 37°C. The 3,3′,5,5′-tetramethylbenzidine (TMB) substrate was then added as per the manufacturer\'s guidelines, and the enzyme-substrate reaction was stopped after 20 min by adding 50 μL of 2 N H~2~SO~4~. The absorbance was measured at 450 nm, taking 540 nm as the reference wavelength as per the manufacturer\'s guidelines. All experiments were carried out in triplicate and the absorbance of the blank (0 ng mL^−1^ HFA in 0.1 M PBS, pH 7.4) was subtracted from all assay values.

The conventional sandwich ELISA was performed as per the manufacturer\'s guidelines provided in the product information sheet without any modification. Various experimental process controls were employed to determine the efficiency of the BSA blocking, non-specific interactions of BSA with HFA, biotinylated anti-HFA and streptavidin-conjugated horseradish peroxidase (SA-HRP), and non-specific interaction of capture anti-HFA with biotinylated anti-HFA. The capture antibody being used in the commercial HFA ELISA kit is polyclonal mouse anti-HFA, while the detection antibody is monoclonal biotinylated goat anti-HFA. The commercial kit also states that the sandwich ELISA exhibits no cross-reactivity or interference with several recombinant human analytes (bone morphogenetic protein-2 (BMP-2), BMP-4, BMP-6, cathepsin V, matrix metalloproteinase-2 (MMP-2), MMP-9, transforming growth factor-β1 (TGF-β1), TGF-β2) and recombinant mouse fetuin A.

All datasets were subjected to standard curve analysis using SigmaPlot software, version 11.2. The EC~50~, *R*^2^ and Hill slope values were determined from the report generated by the software during standard curve analysis based on a four-parameter logistic function. The analytical sensitivity and LOD are calculated by the standard formulae, as mentioned below and further specified in the literature[@b17][@b22][@b36][@b37]. where *OD.~LOD~* and *OD.~AS~* are the optical densities corresponding to LOD and analytical sensitivity, respectively; *OD.~Blank~* is the optical density of the blank; and *SD.~Min\ Analyte\ Conc.~* and *SD.~Blank~* are the standard deviations of the minimum analyte concentration and the blank, respectively.

Buffers and solutions were prepared in Milli-Q deionized water. The dilution of all HFA assay components and BSA was made in 0.1 M PBS, whereas KOH and APTES were diluted in deionized water. The HFA-spiked samples were prepared by admixing various concentrations of HFA in diluted human plasma and whole blood. The HFA dilution was made in BSA-preblocked glass vials, prepared by incubation with 1% (w/v) BSA for 30 min to minimize analyte loss due to non-specific adsorption on sample tube surfaces and/or altered immunogenicity[@b38]. Deionized water and PBS washings were done five times with 300 μL of the respective solutions, while 100 μL was taken for other solutions, i.e. 1% KOH, anti-HFA solution (where anti-HFA was mixed with 1% APTES in the ratio of 1:1 (v/v)), HFA, biotinylated anti-HFA, SA-HRP and TMB substrate. Unless otherwise indicated, the assay temperature and other protocols were maintained at 37°C using a thermostat while the absorbance was measured by a Tecan Infinite M200 Pro microplate reader. The details of the materials used and the characterization experiments performed are provided in the [supplementary information](#s1){ref-type="supplementary-material"}.
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![One-step antibody immobilization-based sandwich ELISA procedure for the detection of human fetuin A (HFA).](srep04407-f1){#f1}

![One-step antibody (Ab) immobilization-based sandwich ELISA.\
(a) Detection of HFA by the NIF, covalent immobilization format (CovIF)-based[@b5][@b9] and conventional immobilization format (CIF)-based (passive adsorption-based) sandwich ELISA procedures. (b) Specific HFA detection with respect to various experimental process controls. (c) Detection of HFA spiked in PBS (0.1 M, pH 7.4), diluted human whole blood and diluted human plasma. (d) Detection of HFA by the anti-HFA Ab-bound MTPs stored in 0.1 M PBS, pH 7.4 at 4°C for 8 weeks. All experiments were done in triplicate with the error bars representing the standard deviation.](srep04407-f2){#f2}

![FTIR spectra pertaining to the APTES-functionalization and the immobilization of antibody on polystyrene (PS) surface.](srep04407-f3){#f3}

![Immunoassays based the NIF for (a) C-reactive protein (CRP), (b) human albumin and (c) human lipocalin-2.\
The NIF-based immunoassays were compared with the CIF and CovIF-based sandwich ELISAs. All experiments were done in triplicate with the error bars representing the standard deviation.](srep04407-f4){#f4}

###### Analytical comparison of the NIF with the conventional immobilization format (CIF) and covalent immobilization format (CovIF)-based[@b5][@b9] sandwich ELISAs for the detection of HFA

                                                   NIF[1](#t1-fn1){ref-type="fn"}   CovIF[2](#t1-fn2){ref-type="fn"}   CIF[3](#t1-fn3){ref-type="fn"}
  ----------------------------------------------- -------------------------------- ---------------------------------- --------------------------------
  Time required for antibody immobilization (h)                 0.5                               2.5                                14
  Assay duration (h)                                            \~4                               \~6                               \~20
  Detection range (pg mL^−1^)                               4.9--20,000                       9.8--20,000                       151--20,000
  LOD (pg mL^−1^)                                                7                                 12                               226
  Analytical sensitivity (pg mL^−1^)                             10                                30                               510
  EC~50~ (ng mL^−1^)                                            2.6                               3.4                               5.8
  \% CV                                                                                                                               
  Intra-day (n = 5)                                           1.2--8.5                         2.4--10.4                         4.7--17.4
  Inter-day (n = 5)                                          2.1--10.2                         1.7--17.6                         3.6--20.0
  Assays on various substrates                                  Yes                               Yes                                No
  Requirement for crosslinkers                                   No                               Yes                                No

^1^NIF: new immobilization format by diluting antibody in APTES followed by physical adsorption on the microtiter plate (MTP).

^2^CovIF: covalent immobilization format by covalent crosslinking of antibody on an APTES modified MTP surface with EDC.

^3^CIF: conventional immobilization format by physical adsorption of antibody on the MTP.

###### Determination of spiked HFA concentrations in diluted human whole blood and plasma by NIF- and CIF-based sandwich ELISAs. The experiments were performed in triplicate, while the results are presented as mean ± S.D.

  Sample matrix                Added conc. (in ng/mL)   NIF-based sandwich ELISA   CIF-based sandwich ELISA
  --------------------------- ------------------------ -------------------------- --------------------------
  Diluted human whole blood              20                   20.1 ± 0.19                20.2 ± 0.18
                                         10                   10.2 ± 0.16                10.3 ± 0.24
                                         5                     5.0 ± 0.17                 5.1 ± 0.09
                                        2.5                    2.4 ± 0.09                 2.5 ± 0.05
                                        1.2                    1.3 ± 0.06                 1.4 ± 0.05
                                        0.6                    0.5 ± 0.03                 0.7 ± 0.03
                                        0.3                    0.3 ± 0.01                 0.4 ± 0.02
  Diluted human plasma                   20                   20.2 ± 0.15                20.1 ± 0.17
                                         10                   10.1 ± 0.18                 9.8 ± 0.16
                                         5                     4.9 ± 0.19                 4.7 ± 0.18
                                        2.5                    2.5 ± 0.11                 2.7 ± 0.12
                                        1.2                    1.2 ± 0.08                 1.3 ± 0.09
                                        0.6                    0.6 ± 0.04                 0.5 ± 0.03
                                        0.3                    0.3 ± 0.02                 0.3 ± 0.01

###### Comparison of NIF with various sandwich ELISA procedures and the commercial kits for the detection of HFA

  Manufacturer/Immunoassay Procedures         Antibody binding    Sensitivity (ng mL^−1^)                                               References
  ----------------------------------------- -------------------- ------------------------- ----------------------------------------------------------------------------------------------------
  New ELISA format (NIF)                          One-step                 0.01                                                         This work
  ELISA-covalent binding of antibody              Covalent                 0.03             This work[@b5] using the covalent immobilization of the antibody as described by Dixit et al.[@b5]
  Conventional ELISA                         Passively adsorbed             0.5                                                         This work
  RnD systems                                Passively adsorbed            0.37                                         <http://www.rndsystems.com/pdf/DY1184.pdf>
  Biovendor                                  Passively adsorbed            0.35                         <http://www.biovendor.com/product/immunoassays/fetuin-a-ahsg-human-elisa>
  Alpco Diagnostics                          Passively adsorbed            5.00                                      <http://www.alpco.com/pdfs/43/43-NSEHU-E01.pdf>
  Immunology Consultants Laboratory, Inc.    Passively adsorbed            6.25                                      <http://www.life-sciences.com.br/pdf/icllab.pdf>
  Genway Biotech, Inc.                       Passively adsorbed            6.25                           <http://www.genwaybio.com/images/gw_tds/elisa_kits/40-374-130036.pdf>
  Assay Pro                                  Passively adsorbed            6.25                                      <http://www.assaypro.com/datasheet/eg3501_1.pdf>
